Oglesby v. Medtronic, Inc.
Opinion
United States Court of Appeals for the Fifth Circuit United States Court of Appeals Fifth Circuit
____________ FILED March 26, 2024
No. 23-50274
Lyle W. Cayce
____________ Clerk
GeorgAnn Oglesby; Stephen Oglesby,
Plaintiffs—Appellants,
versus
Medtronic, Incorporated; Medtronic USA, Incorporated; Integra LifeSciences Corporation,
Defendants—Appellees.
Appeal from the United States District Court for the Western District of Texas USDC No. 5:20-CV-1267
Before King, Ho, and Engelhardt, Circuit Judges. Per Curiam:* GeorgAnn Oglesby sued Medtronic, Inc., Medtronic USA, Inc., and Integra LifeSciences Corporation, asserting manufacturing defect, negligence , and failure-to-warn claims after a medical device implanted in Oglesby’s body disintegrated. The district court granted summary judgment in favor of Medtronic and Integra. We affirm.
*
This opinion is not designated for publication. See 5th Cir. R. 47.5.
No. 23-50274
In July 2019, Oglesby had surgery to address a cyst on her cervical spine. During the surgery, Oglesby’s physician implanted a Durepair Dura Regeneration Matrix—a medical device designed to be used as a patch to repair dura matter, which is a membrane protecting the brain and spinal cord. The Durepair device was manufactured by Integra and sold by Medtronic.
Soon after the surgery, Oglesby experienced severe headaches and other serious symptoms. Oglesby underwent another surgery in which her physician discovered that the Durepair patch had largely disintegrated, causing a cerebrospinal fluid leak.
Oglesby and her husband sued Medtronic in Texas state court.
Medtronic removed the case to federal court, and Oglesby later amended her complaint to include Integra as a defendant. She asserts manufacturing defect, negligence, and failure-to-warn claims.
Medtronic and Integra both filed motions for summary judgment.
The magistrate judge’s report and recommendation concluded (1) that Oglesby’s manufacturing defect and negligence claims failed because she did not identify a specific defect in the Durepair product and (2) that Oglesby’s failure-to-warn claim failed because Oglesby could not show that her doctor would have read the warning even if an adequate warning was provided. The district court adopted the magistrate judge’s report and recommendation, granted both summary judgment motions, and dismissed the case. Oglesby appealed.
We review a district court’s grant of summary judgment de novo.
Norman v. Bodum USA, Inc., 44 F.4th 270, 272 (5th Cir. 2022). Courts grant summary judgment “if the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a). Summary judgment is inappropriate, however, if, viewing the evidence in the light most favorable to the
No. 23-50274
nonmovant, “a reasonable jury could return a verdict for the nonmoving party.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248 (1986).
Oglesby’s claims are governed by Texas law. We first address her manufacturing defect claim. “A manufacturing defect exists when a product deviates, in its construction or quality, from the specifications or planned output in a manner that renders it unreasonably dangerous.” Ford Motor Co. v. Ridgway, 135 S.W.3d 598, 600 (Tex. 2004). “A plaintiff must prove that the product was defective when it left the hands of the manufacturer and that the defect was a producing cause of the plaintiff’s injuries.” Id.
While “[a] manufacturing defect may be established exclusively through circumstantial evidence,” Norman, 44 F.4th at 272, product failure alone is not enough to prevail on a manufacturing defect claim. See Ford Motor Co. v. Ledesma, 242 S.W.3d 32, 42 (Tex. 2007). Instead, the plaintiff must identify a specific defect in how the product was manufactured. See Gharda USA, Inc. v. Control Sols., Inc., 464 S.W.3d 338, 352 (Tex. 2015) (“To be successful on a manufacturing defect claim, the plaintiff must identify a specific defect by competent evidence and rule out other possible causes of the damage.”); Ledesma, 242 S.W.3d at 42 (“While a products liability claim does not of course require proof of manufacturer negligence, the deviation from design that caused the injury must be identified.”).
However, Oglesby has not attempted to identify any specific way in which the Durepair product deviated from its design. She acknowledges as much in her briefing, which states that she “has not pointed to the specific mechanism by which the Durepair device was defective.” Instead, she argues that the law does not require her to allege a specific defect, relying heavily on older cases from this court and the Texas courts of appeals. See Ayres v. Sears, Roebuck & Co., 789 F.2d 1173, 1175 (5th Cir. 1986) (stating that plaintiffs “need not establish the specific feature which made the product
No. 23-50274
defective”). See also Bell Aerospace Corp. v. Anderson, 478 S.W.2d 191, 197 (Tex. Civ. App.—El Paso 1972, writ ref’d n.r.e.); Baxter Healthcare Corp. v. Grimes, No. 05-95-01682-CV, 1998 WL 548729, *10 (Tex. App.—Dallas Aug. 31, 1998, no pet.).
But “[t]o determine Texas law, this court looks first to the final decisions of the Texas Supreme Court.” Austin v. Kroger Tex. L.P., 746 F.3d 191, 196 (5th Cir. 2014). In recent years, the Texas Supreme Court has repeatedly stated that identifying a specific defect is essential to a manufacturing defect claim. See Gharda USA, 464 S.W.3d at 352; Ledesma, 242 S.W.3d at 42; Nissan Motor Co. v. Armstrong, 145 S.W.3d 131, 137 (Tex. 2004) (“[A] specific defect must be identified by competent evidence.”). See also Norman, 44 F.4th at 272 (“[P]laintiffs must allege a specific deviation from the product’s intended design that allegedly caused the injury.”).
Oglesby points to evidence indicating that the Durepair patch was not designed to dissolve, but that it nevertheless sometimes disintegrates. But none of this evidence establishes a specific manufacturing defect. See Ledesma, 242 S.W.3d at 42 (noting that deviation from design “serves the essential purpose of distinguishing a manufacturing defect from a design defect”); Norman, 44 F.4th at 272 (“In a manufacturing defect case, . . . the plaintiff must present proof of a manufacturer’s intended design, from which the actual product in question deviated as a result of a defect in the manufacturing process.”).
Oglesby also cites expert testimony that, “within a reasonabl[e]
degree of engineering and scientific probability, and on a more-likely-thannot basis, the Subject Durepair contained a manufacturing defect and/or reacted adversely with the Adherus sealant which led to its ‘disintegration,’ as noted by [Oglesby’s physician].” But this testimony also does not establish the specific manufacturing defect that allegedly caused the
No. 23-50274
disintegration. Nor does it support an inference that such a defect, as opposed to an adverse reaction with the sealant, more likely than not caused the disintegration. “When the circumstances are equally consistent with either of two facts, neither fact may be inferred.” City of Keller v. Wilson, 168 S.W.3d 802, 813 (Tex. 2005) (internal quotation omitted).1 While a specific defect may be proven by circumstantial evidence, that does not eliminate the requirement to allege the existence of a specific defect in the first place. Oglesby failed to do so. Under Texas law, this fact alone means that her manufacturing defect claim cannot succeed. The district court therefore correctly granted summary judgment for Integra and Medtronic on Oglesby’s manufacturing defect claim.
Free access — add to your briefcase to read the full text and ask questions with AI
Oglesby v. Medtronic, Inc. (Oglesby v. Medtronic, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.